AviaraDx CUP Technology Highlighted in Case Study Published in New England Journal of Medicine
Complete the form below to unlock access to ALL audio articles.
AviaraDx, Inc. has announced the publication of a case study, in the September 7th issue of the New England Journal of Medicine, that utilized an assay based upon the company's Molecular Cancer Identification (MCID) technology for the diagnosis of cancer of unknown primary.
The case study was based on a CUP assay developed by a European licensee of AviaraDx.
"We are pleased NEJM has chosen to publish this case study, which provides an example of the benefits that the AviaraDx molecular profiling technology brings to the diagnostic evaluation of these often difficult cases," said Mark Erlander, Ph.D., Chief Scientific Officer of AviaraDx, Inc.
"Correctly identifying the primary tumor origin in CUP patients provides the clinician with options for improved therapy regimens, resulting in better patient prognosis."
